Form 4: HeartBeam Director George de Urioste Receives Equity Awards

HeartBeam, Inc. Director George de Urioste reported the acquisition of restricted stock units and stock options, aligning his interests with shareholders.

Summary

• Director George de Urioste of HeartBeam, Inc. reported changes in his beneficial ownership of company securities.
• He was granted 60,483 Restricted Stock Units (RSUs) on July 11, 2025, each representing a contingent right to receive one share of Common Stock. These RSUs vest on the earlier of July 11, 2026, or the date of the Issuer's 2026 annual meeting, subject to his continued service as an Outside Director.
• Additionally, on September 30, 2025, he received options to purchase 45,454 shares of Common Stock at an exercise price of $1.65 per share. These options vest in two equal tranches: half on October 1, 2025, and the remaining half on January 1, 2026, based on a July 1, 2025, vesting commencement date.
• Following these reported transactions, de Urioste directly beneficially owns 57,146 shares of Common Stock, 60,483 shares underlying RSUs, and 89,454 shares underlying stock options.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive signal for management alignment and retention, indicating confidence in future performance, though it's a routine compensation event.

Positives

• Grant of 60,483 Restricted Stock Units (RSUs) to Director George de Urioste, aligning his long-term interests with shareholder value.
• Grant of options to purchase 45,454 shares of Common Stock at an exercise price of $1.65, providing further performance incentives.
• The equity awards are issued under the company's 2022 Equity Incentive Plan, indicating a structured approach to director compensation and governance.

Risks

• Vesting of Restricted Stock Units and stock options is contingent on George de Urioste continuing to serve as an Outside Director through the specified vesting dates.

Future Outlook

The equity grants are designed to align the director's long-term interests with the company's performance, with vesting contingent on continued service.

Management Comments

• The equity awards are issued from the Company's 2022 Equity Incentive Plan.

Industry Context

This filing reflects a standard practice in corporate governance where equity awards are used to compensate and incentivize directors, aligning their financial interests with the long-term success of the company in the medical technology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with long-term company performance.
• Management: Strengthens retention and motivation of a key director.

Next Steps

• Continued service of George de Urioste as an Outside Director for vesting of equity awards.
• Vesting of 50% of options on October 1, 2025.
• Vesting of remaining 50% of options on January 1, 2026.
• Vesting of RSUs on the earlier of July 11, 2026, or the 2026 annual meeting of stockholders.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice to align management interests with shareholders. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell, but rather confirms ongoing governance practices.

Keywords

HeartBeam, BEAT, SEC Form 4, Insider Trading, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, George de Urioste